Osteoporosis and Related Bone Metabolic Disease
Many heterogeneous causes (e.g., metabolic, inflammatory, autoimmune, vascular, and renal diseases, and even drugs), collectively grouped as secondary causes of osteoporosis, may lead to bone loss or damage to architecture through a number of mechanisms. Although these secondary causes of osteoporos...
में बचाया:
| स्वरूप: | Online |
|---|---|
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| विषय: | |
| ऑनलाइन पहुंच: | ONIX_20230405_9783036563480_10 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| _version_ | 1869522750099423232 |
|---|---|
| collection | Directory of Open Access Books |
| description | Many heterogeneous causes (e.g., metabolic, inflammatory, autoimmune, vascular, and renal diseases, and even drugs), collectively grouped as secondary causes of osteoporosis, may lead to bone loss or damage to architecture through a number of mechanisms. Although these secondary causes of osteoporosis are the most frequently observed causes of unexpected bone loss, they can only be diagnosed via a high degree of suspicion and clinical experience and by performing the appropriate investigations. In inflammatory disorders such as rheumatoid arthritis or chronic inflammatory bowel diseases, as well as vascular diseases, T-cell activation, and consequently pro-inflammatory cascades, trigger the increased expression of T-cell-derived RANKL. In addition, a new biomarker signature of bone-related miRNAs is promising in certain clinical features. Glucocorticoids, often used to control disease activity, decrease the number and function of osteoblasts and inhibit OPG expression. The ubiquitous occurrence of disease-related secondary changes in bone metabolism implies that numerous medical disciplines need to interact. Screening for secondary causes of osteoporosis and the search for new modes of action should present a substantial aspect of osteoporosis management. In the book, the current management of osteoporosis and related metabolic bone diseases is discussed. |
| format | Online |
| id | doab-20.500.12854ir-98731 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-987312024-03-30T23:23:04Z Osteoporosis and Related Bone Metabolic Disease Resch, Heinrich osteoporosis diabetes metformin carcinoma in situ National Health Insurance Research Database bone mineral density fracture bone fragility psoriasis psoriatic arthritis meta-analysis premature ovarian insufficiency DXA menopause Crohn’s disease bone microstructure bone loss fractal-based analysis glucocorticoid treatment risk factors imaging methods bone biomaterial scaffolds 3D printing strontium ranelate testosterone men fragility fracture fracture risk imminent fracture risk bone microstructural deterioration cortical porosity high resolution peripheral quantitative computed tomography stress fracture denosumab kidney transplantation CKDMBD vertebral fractures Gaucher disease TRAP5b OPG RANKL biomarker lyso-Gb1 initiation timing second fracture adverse events n/a thema EDItEUR::M Medicine and Nursing Many heterogeneous causes (e.g., metabolic, inflammatory, autoimmune, vascular, and renal diseases, and even drugs), collectively grouped as secondary causes of osteoporosis, may lead to bone loss or damage to architecture through a number of mechanisms. Although these secondary causes of osteoporosis are the most frequently observed causes of unexpected bone loss, they can only be diagnosed via a high degree of suspicion and clinical experience and by performing the appropriate investigations. In inflammatory disorders such as rheumatoid arthritis or chronic inflammatory bowel diseases, as well as vascular diseases, T-cell activation, and consequently pro-inflammatory cascades, trigger the increased expression of T-cell-derived RANKL. In addition, a new biomarker signature of bone-related miRNAs is promising in certain clinical features. Glucocorticoids, often used to control disease activity, decrease the number and function of osteoblasts and inhibit OPG expression. The ubiquitous occurrence of disease-related secondary changes in bone metabolism implies that numerous medical disciplines need to interact. Screening for secondary causes of osteoporosis and the search for new modes of action should present a substantial aspect of osteoporosis management. In the book, the current management of osteoporosis and related metabolic bone diseases is discussed. 2023-04-05T12:48:11Z 2023-04-05T12:48:11Z 2023 book ONIX_20230405_9783036563480_10 9783036563480 9783036563497 https://directory.doabooks.org/handle/20.500.12854/98731 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/6738 https://mdpi.com/books/pdfview/book/6738 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-6349-7 10.3390/books978-3-0365-6349-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036563480 9783036563497 164 Basel open access |
| spellingShingle | osteoporosis diabetes metformin carcinoma in situ National Health Insurance Research Database bone mineral density fracture bone fragility psoriasis psoriatic arthritis meta-analysis premature ovarian insufficiency DXA menopause Crohn’s disease bone microstructure bone loss fractal-based analysis glucocorticoid treatment risk factors imaging methods bone biomaterial scaffolds 3D printing strontium ranelate testosterone men fragility fracture fracture risk imminent fracture risk bone microstructural deterioration cortical porosity high resolution peripheral quantitative computed tomography stress fracture denosumab kidney transplantation CKDMBD vertebral fractures Gaucher disease TRAP5b OPG RANKL biomarker lyso-Gb1 initiation timing second fracture adverse events n/a thema EDItEUR::M Medicine and Nursing Osteoporosis and Related Bone Metabolic Disease |
| title | Osteoporosis and Related Bone Metabolic Disease |
| title_full | Osteoporosis and Related Bone Metabolic Disease |
| title_fullStr | Osteoporosis and Related Bone Metabolic Disease |
| title_full_unstemmed | Osteoporosis and Related Bone Metabolic Disease |
| title_short | Osteoporosis and Related Bone Metabolic Disease |
| title_sort | osteoporosis and related bone metabolic disease |
| topic | osteoporosis diabetes metformin carcinoma in situ National Health Insurance Research Database bone mineral density fracture bone fragility psoriasis psoriatic arthritis meta-analysis premature ovarian insufficiency DXA menopause Crohn’s disease bone microstructure bone loss fractal-based analysis glucocorticoid treatment risk factors imaging methods bone biomaterial scaffolds 3D printing strontium ranelate testosterone men fragility fracture fracture risk imminent fracture risk bone microstructural deterioration cortical porosity high resolution peripheral quantitative computed tomography stress fracture denosumab kidney transplantation CKDMBD vertebral fractures Gaucher disease TRAP5b OPG RANKL biomarker lyso-Gb1 initiation timing second fracture adverse events n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | osteoporosis diabetes metformin carcinoma in situ National Health Insurance Research Database bone mineral density fracture bone fragility psoriasis psoriatic arthritis meta-analysis premature ovarian insufficiency DXA menopause Crohn’s disease bone microstructure bone loss fractal-based analysis glucocorticoid treatment risk factors imaging methods bone biomaterial scaffolds 3D printing strontium ranelate testosterone men fragility fracture fracture risk imminent fracture risk bone microstructural deterioration cortical porosity high resolution peripheral quantitative computed tomography stress fracture denosumab kidney transplantation CKDMBD vertebral fractures Gaucher disease TRAP5b OPG RANKL biomarker lyso-Gb1 initiation timing second fracture adverse events n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20230405_9783036563480_10 |